Drug firm AstraZeneca Pharma India Ltd on Monday (November 17) said the company and Sun Pharmaceutical Industries Ltd have entered into a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India.

The agreement is aimed at accelerating the availability of SZC, described as an innovative and highly effective treatment for Hyperkalaemia, to a wider patient base across the country. As part of the arrangement, both companies will promote, market and distribute SZC in India under separate brand names.

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will continue to retain the intellectual property rights for SZC. The company will also hold the Marketing Authorisation along with the import license f

See Full Page